Mydecine Innovations Group Inc.
MYCOF
$0.0045
-$0.0006-11.77%
| Weiss Ratings | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.75 | |||
| Price History | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 7.14% | |||
| 30-Day Total Return | 25.00% | |||
| 60-Day Total Return | 7.14% | |||
| 90-Day Total Return | -35.71% | |||
| Year to Date Total Return | -26.23% | |||
| 1-Year Total Return | -53.13% | |||
| 2-Year Total Return | -98.74% | |||
| 3-Year Total Return | -99.91% | |||
| 5-Year Total Return | -99.86% | |||
| 52-Week High % Change | -79.63% | |||
| 52-Week Low % Change | 4,400.00% | |||
| Price | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.02 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Mar 12, 2024 | |||
| 52-Week High Price (Date) | Apr 26, 2024 | |||
| Valuation | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 277.90K | |||
| Enterprise Value | 5.07M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.20 | |||
| Earnings Per Share Growth | -48.44% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.02 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -0.99 | |||
| Enterprise Value/EBIT | -0.99 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 61.76M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 687 2038 | |||
| Address | 1075 West Georgia Street Vancouver, BC V6E 3C9 | |||
| Website | www.mydecine.com | |||
| Country | Canada | |||
| Year Founded | 2013 | |||
| Profitability | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -187.16% | |||
| Return on Equity | -- | |||
| Income Statement | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -5.12M | |||
| EBIT (TTM) | -5.13M | |||
| Net Income (TTM) | -10.73M | |||
| Net Income Avl. to Common (TTM) | -10.73M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -65.51% | |||
| EPS Diluted (TTM) | -0.20 | |||
| EPS Diluted Growth (Q YOY) | 23.13% | |||
| Balance Sheet | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 44.50K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 132.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -12.91M | |||
| Current Ratio (Q) | 0.010 | |||
| Book Value Per Share (Q) | -$0.21 | |||
| Total Assets (Q) | 132.00K | |||
| Total Current Liabilities (Q) | 13.05M | |||
| Total Debt (Q) | 4.83M | |||
| Total Liabilities (Q) | 13.05M | |||
| Total Common Equity (Q) | -12.91M | |||
| Cash Flow | MYCOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | -684.70K | |||
| Net Change in Cash (TTM) | 31.30K | |||
| Levered Free Cash Flow (TTM) | 2.96M | |||
| Cash from Operations (TTM) | 716.00K | |||
